Coronavirus interactions in drug discovery - optimization and implementation

Bidragets beskrivning

Last November infections of a new kind of coronavirus were announced but no one could have then anticipated how large impact this new virus (SARS-CoV-2) would cause globally only few week after finding it. Now this SARS-CoV-2 has spread around almost every place on Earth including Finland. In this project a consortium of four groups from University of Helsinki and University of Eastern Finland plan to tackle the task in identifying molecules (drugs) that would interfere replication of the virus. Members of the consortia coverer different disciplines from virology to protein-protein interaction and structural biology ranging until drug discovery. We are planning to use a multiplicinary approach to test existing drugs that have already been allowed to be used in humans. We are testing which drugs or combination of drugs against human proteins would inhibit or slow down replication of the virus. This is the fastest way to get drugs against this virus.
Visa mer

Startår

2020

Slutår

2022

Beviljade finansiering



Sarah Butcher Orcid -palvelun logo
321 237 €

Rollen i Finlands Akademis konsortium

Partner

Övriga parter i konsortiet

Partner
Östra Finlands universitet (336473)
260 494 €
Leader
Helsingfors universitet (336470)
404 291 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt med särskild inriktning

Övriga uppgifter

Finansieringsbeslutets nummer

336471

Vetenskapsområden

Växtbiologi, mikrobiologi, virologi

Forskningsområden

Mikrobiologia

Temaområden

Lisätalousarvio III 2020

Identifierade teman

covid, pandemic, vaccines